scPharmaceuticals Provides FUROSCIX (furosemide injection) Commercial Update

Commercial launch planned for February 20, 2023

BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that the company is targeting February 20, 2023 as the date for commercial availability of FUROSCIX (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure. FUROSCIX is not indicated for emergency situations or in patients with acute pulmonary edema. FUROSCIX Infusor will deliver only an 80-mg dose. 

“Since obtaining FDA approval for FUROSCIX in October 2022, we have been working tirelessly to prepare for a robust commercial launch, which is targeted for February 20^th,” stated John Tucker, Chief Executive Officer. “We have assembled a world class commercial team, including the recent promotion of Steve Parsons to SVP of Commercial, and we believe we have built sufficient inventory for anticipated launch and ongoing demand.”

“We anticipate that all Medicare Part D and Medicaid beneficiaries will have reimbursed access to FUROSCIX on day one and that approximately 60% of all heart failure patients will have fixed tier co-pays (≤ $100) at launch and we continue working hard to expand this to greater than 75% fixed tier co-pays. Discussions with payers regarding coverage expansion are ongoing and productive. All in all, I am very pleased with our progress, and look forward to what I expect will be a very successful launch,” Mr. Tucker added.

“Since FDA approval, we have engaged in a broad market awareness campaign to introduce FUROSCIX as a new treatment option for heart failure patients pre- or post-hospital admission,” stated Steve Parsons, Senior Vice President of Commercial. “There is a clear need for a better way to manage heart failure patients, and a significant opportunity to reduce unnecessary hospital admissions, and I believe FUROSCIX addresses this need. I look forward to working to make FUROSCIX broadly available to all heart failure patients with congestion and their treating physicians.”